Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pluristem Therapeutics has scaled-up the formulation and production process of its Placental eXpanded (PLX) cells for the large scale commercial and clinical trial use.
Subscribe to our email newsletter
The new amplified process that included the optimization of the growth conditions and reduction of open manipulation steps will enable huge production of live cells.
Pluristem chairman and CEO Zami Aberman said the new large scale manufacturing process will allow the company to run numerous trials simultaneously around the globe besides preparing for potential commercial availability.
"Our progress with both our manufacturing process and facility are well on track," Aberman added.
The improved process will aid in lowering costs besides advancing the safety and aseptic quality of the product.
Harvesting, purification, the closed system washing integration and final packaging steps were automated.
Pluristem completed testing all the integrated changes and is expected to incorporate in its new Israel production site, the construction of which is nearing completion.